Transglutaminase 2 expression is associated with increased risk of lymph node metastasis and recurrence in papillary thyroid cancer.

[1]  Hao Zhang,et al.  The NEAT1_2/miR-491 Axis Modulates Papillary Thyroid Cancer Invasion and Metastasis Through TGM2/NFκb/FN1 Signaling , 2021, Frontiers in Oncology.

[2]  M. Park,et al.  Identifying risk factors of lateral lymph node recurrence in clinically node-negative papillary thyroid cancer , 2018, Medicine.

[3]  Kyung-Hee Kim,et al.  Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition , 2018, Cancers.

[4]  J. Casal,et al.  Prognostic role of tissue transglutaminase 2 in colon carcinoma , 2016, Virchows Archiv.

[5]  J. H. Kang,et al.  Discovery of a novel target for renal cell carcinoma: transglutaminase 2 , 2016, Cell Death and Disease.

[6]  O. Sanli,et al.  The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma , 2015, World Journal of Urology.

[7]  Chieh-Hsi Wu,et al.  A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia , 2015, Clinical endocrinology.

[8]  C. Bournaud,et al.  Follow-up of differentiated thyroid carcinoma. , 2015, Annales d'endocrinologie.

[9]  K. Coombes,et al.  Transglutaminase 2 expression in acute myeloid leukemia: Association with adhesion molecule expression and leukemic blast motility , 2013, Proteomics.

[10]  S. Roman,et al.  Differentiated Thyroid Cancer Presenting with Distant Metastases: A Population Analysis Over Two Decades , 2013, World Journal of Surgery.

[11]  Soo-Youl Kim,et al.  Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[12]  T. Fahey,et al.  Impact of Prophylactic Central Neck Lymph Node Dissection on Early Recurrence in Papillary Thyroid Carcinoma , 2010, World Journal of Surgery.

[13]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[14]  M. Hočevar,et al.  Extent of Thyroidectomy and Lymphadenectomy in 254 Patients With Papillary Thyroid Microcarcinoma: A Single-Institution Experience , 2009, Annals of Surgical Oncology.

[15]  A. Sood,et al.  Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. , 2008, Cancer research.

[16]  M. Griffin,et al.  Tissue transglutaminase in tumour progression: friend or foe? , 2007, Amino Acids.

[17]  C. Miller,et al.  Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy , 2007, Oncogene.

[18]  Amit Verma,et al.  Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells , 2007, Oncogene.

[19]  Huamin Wang,et al.  Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. , 2006, Cancer research.

[20]  P. Hall,et al.  Clinically significant prognostic factors for differentiated thyroid carcinoma , 2006, Cancer.

[21]  M. Chicoine,et al.  Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas , 2005, Molecular Cancer Therapeutics.

[22]  M. Salvatore,et al.  Follow-up of differentiated thyroid carcinoma. , 2004, Minerva endocrinologica.

[23]  E. Pearce,et al.  Papillary thyroid microcarcinoma outcomes and implications for treatment. , 2004, The Journal of clinical endocrinology and metabolism.

[24]  G. Johnson,et al.  Intracellular Localization and Activity State of Tissue Transglutaminase Differentially Impacts Cell Death* , 2004, Journal of Biological Chemistry.

[25]  J. Shah,et al.  Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. , 2003, Journal of the American College of Surgeons.

[26]  Mauro Piacentini,et al.  Transglutaminase 2: an enigmatic enzyme with diverse functions. , 2002, Trends in biochemical sciences.

[27]  S. Ikehara,et al.  Increased expression of integrin β‐4 in papillary thyroid carcinoma with gross lymph node metastasis , 2002, Pathology international.

[28]  S. Akimov,et al.  Tissue Transglutaminase Is an Integrin-Binding Adhesion Coreceptor for Fibronectin , 2000, The Journal of cell biology.

[29]  A. Baldini,et al.  The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization. , 1994, Genomics.

[30]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[31]  R. Tuttle.  Risk-adapted management of thyroid cancer. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[32]  R. Moncayo,et al.  beta 1-Integrin expression in papillary thyroid carcinoma. , 1998, Anticancer research.